Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapy Follow-on dosing with a 55 mg dose of […]